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Abstract
Context and objective: We evaluated the predictive value of serum cartilage oligomeric matrix
protein (sCOMP) levels over 20 years on the development of radiographic (RKOA) and painful
knee osteoarthritis (KOA) in a longitudinal cohort of middle-aged women.
Materials and methods: Five hundred and ninety-three women with no baseline KOA underwent
5-year knee radiographs over 20-years and were asked about knee pain a month before each
assessment. A repeated measures logistic regression model was used where the outcomes
were recorded at 5, 10, 15 and 20-years follow-up.
Results: The highest quartile of sCOMP was associated with increased risk of RKOA with overall
OR of 1.97 (95% CI: 1.33–2.91) over 20 years when compared with the lowest sCOMP quartile.
The association with painful KOA was similar and also independent, but only when the fourth
and third sCOMP quartiles were compared.
Discussion and conclusion: This study demonstrates that sCOMP levels are predictive of
subsequent structural changes and incidence of painful KOA, independently of age and BMI.
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Introduction
Knee osteoarthritis (KOA) is a highly prevalent disease of the
largest synovial joint affecting quality of life, mobility and it
is linked with an excess mortality (Cooper & Arden, 2011;
Kluzek et al., 2015; Liu et al., 2015; Murphy et al., 2008;
Nu¨esch et al., 2011; Semanik et al., 2015; Szoeke et al.,
2006). The lifetime risk of diagnosed symptomatic KOA is
around 45%, occurring relatively early, with a median age of
55 years at diagnosis (Losina et al., 2013; Murphy et al.,
2008). It is estimated that 10% of the UK population over 55
years has disabling symptoms due to KOA (Peat, 2001). The
lifetime risk of receiving a total knee replacement is also
substantial, with values of 8.1% for men and 10.8% for
women, respectively (Culliford et al., 2012). KOA has many
known risk factors, including age, female gender, obesity,
history of knee injury and occupation. There is a need to find
reliable markers that identify individuals with increased risk
of developing KOA.
The cartilage oligomeric matrix protein (COMP) is a
pentameric glycoprotein that was first identified in hyaline
cartilage and fibrocartilage by Fife and colleagues (Fife,
1988; Fife et al., 1991). COMP is derived from several tissue
types, including cartilage, synovium and menisci, and
composed of five equal subunits, each 110 kDa (Mu¨ller
et al., 1998). It is synthesised by chondrocytes and synovial
cells activated by proinflammatory cytokines (Zivanovic´
et al., 2011). The role of COMP is not fully understood.
The presence of a pentameric COMP complex increases the
collagen fibril formation while the presence of the monomeric
COMP decreases it (Hala´sz et al., 2007). Mutations of the
COMP gene are linked with multiple epiphyseal dysplasia, a
disorder of cartilage and bone development (Kim et al.,
2011). Structure and biochemical properties of COMP
suggest it might be involved in tissue storing of vitamin D
(Guo et al., 1998; Ozbek et al., 2002). Synovial COMP
concentrations have been correlated with serum COMP
(sCOMP) levels (Addison et al., 2009). The precise factors
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associated with variation of serum COMP levels remain
incompletely understood. The results from The Johnston
County Osteoarthritis Project demonstrate that ethnicity, sex
and radiographic hip or knee changes are associated with
variation of sCOMP levels (Jordan et al., 2003). Age, weight,
gender and mechanical loading affect the level of sCOMP in
healthy individuals (Bartels et al., 2014; Niehoff et al., 2010;
Verma & Dalal, 2013). Serum COMP levels increase
significantly from 1 h after rising from bed and are affected
by exercise (Kong et al., 2006; Neidhart et al., 2000).
Elevated sCOMP levels have been reported in patients with
chronic inflammatory arthritis compared to healthy children
(Saxne & Heinega˚rd, 1992). High levels of sCOMP have been
observed after a knee injury, with active synovitis and in knee
osteoarthritis (Dahlberg et al., 1994; Lohmander et al., 1994;
Vilı´m et al., 2001). Several studies showed a cross-sectional
association of sCOMP with radiographic KOA (RKOA)
(Fernandes et al., 2007; Kong et al., 2006).
Associations with painful KOA are more complicated.
Higher serum concentrations are linked to self-reported pain
(Kluzek et al., 2014). Feldman and colleagues reported
significantly higher levels in a population with painful
RKOA than in age and sex-matched healthy controls
(Fernandes et al., 2007). However, other studies have shown
that sCOMP levels do not correlate with severity of KOA
symptoms (Lai et al., 2012; Verma & Dalal, 2013) and in a
population with knee pain, no association was found between
sCOMP levels and structural radiographic or MRI changes
(Cibere et al., 2009). In a meta-analysis of cohort and case-
controlled studies, Hoch et al. showed that sCOMP levels are
significantly higher in patients with knee osteoarthritic symp-
toms (Hoch et al., 2011).
In longitudinal studies, individuals with low sCOMP levels
and KOA were found to have a significantly lower rate of
medial cartilage volume loss during the follow-up (Berry
et al., 2010) and those with higher sCOMP levels had a
significantly increased risk of subsequent cartilage loss
(Hunter et al., 2007). In women with RKOA, upward
trajectories of longitudinally acquired sCOMP levels were
associated with higher knee pain and stiffness scores and
increased RKOA severity (Sowers et al., 2009). Individuals
with clinical OA and high sCOMP levels have been found to
be at risk of rapidly progressing debilitating joint disease in a
longitudinal study (Verma & Dalal, 2013).
Blumenfeld and colleagues showed that high baseline
sCOMP levels predict the development of RKOA over 10
years in middle-aged women (Blumenfeld et al., 2013).
Longitudinal associations of baseline COMP levels with
incidence of RKOA in more than 10 years and incidence of
painful KOA are unknown.
The aim of this study is to look at the predictive value of
sCOMP levels over 20 years on the development of RKOA
and the painful KOA in a longitudinal cohort of middle-aged
women.
Methods
Design
Prospective, population-based cohort study of middle-aged
women.
Study population
The Chingford cohort study has been shown to be represen-
tative of middle-aged women in England and their character-
istics have been described in detail previously (Hart &
Spector, 1993a,b). All participants aged 45–64 years were
registered in the same large general practice. Among 1353
women contacted and asked to participate in 1988–1989,
1003 (78% response rate) attended the baseline visit and have
since been examined annually.
Inclusion and exclusion criteria
Only subjects with K/L scores of 0 at baseline in both knees
were included in the analysis. We also excluded women with
any of the following exclusion criteria at baseline or at any
point during follow-up: rheumatoid arthritis, psoriatic arth-
ritis, gout, Paget’s disease, polio, cerebral palsy and chronic
inflammatory demyelinating neuropathy. Women also had to
have pain and radiographic knee data at baseline and during at
least one 5-year interval over a 20-year follow-up. Five
hundred and ninety-three women were included in the
analysis with available biomarkers. The local ethics commit-
tee approved the study protocol and all participants signed an
informed consent form.
Outcomes
The outcomes of interest were the incidence of subject level:
(a) radiographic KOA (RKOA); (b) painful radiographic KOA
and (c) symptomatic KOA during the 20-year follow-up.
RKOA assessed from weight bearing, extended knee X-rays
were obtained every 5 years (years 5, 10, 15 or 20). Incident
RKOA was determined using a K/L score of 2 or more at any
point during follow-up with radiographic data. Women were
asked if they had felt any knee pain in the last month and the
number of painful days of knee pain they had experienced in
the last month. Site-specific knee pain was classified as
positive if they answered ‘‘yes’’ and more than 0 d were
reported. Painful RKOA was classified as positive if they had
both any knee pain and K/L scores of 2 or more, affecting the
same knee joint during the same follow-up visit. Subjects
were classified as having symptomatic RKOA if they had both
knee pain for 15 d or more in the preceding month and K/L
scores of 2 or more, affecting the same knee joint during the
same follow-up time. Those who underwent total knee
replacement during the 20-year follow-up were classified as
having incident RKOA and painful RKOA.
Radiographic KOA assessment
Weight-bearing anteroposterior (AP) plain film extended knee
radiographs were obtained at baseline, year 5, year 10 and
year 15. Digital X-rays were taken in year 20 using protocols
as similar as possible to previous visits (Leyland et al., 2012).
Radiographs were scored individually by a single trained
reader who was blinded to all clinical information except for
study visit and study number. The presence of RKOA was
determined using the Kellgren/Lawrence (K/L) score
(Kellgren & Lawrence, 1957; Kellgren et al., 1963). The
baseline and year 5 radiographs were read by the same two
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observers (DH and TS) and a single reader (DH) graded the
year 10 and year 15 radiographs. As previously reported,
reproducibility of the grading system was high (Spector et al.,
1993). Year 20 radiographs were read by an additional
observer who trained using comparable methods under the
guidance of a previous observer (DH).
Serum COMP levels
Sera were obtained from venous fasting blood during the
second- and third-year follow-ups and stored at 80 C. This
study used an enzyme-linked immunosorbent assay (ELISA)
with an ELISA kit manufactured by AnaMar Medical
(Uppsala, Sweden). The intra- and inter-assay variations
were below 4% and 8%, respectively. The samples were
measured in 2009, when the format was a serum standard.
The assay was validated before testing the samples, a process
that included the sample dilution, determination of measure-
ment range and day-to-day variation. The quantification range
was determined internally by the lab as 2 (lower limit of
quantification) to 35 (upper limit of quantification) U/L. All
samples were measured in the duplicates and within the
measuring range when diluted 4–10 times. Samples were re-
run if intra assay coefficients of variability (CVs) were above
15% or if their values were outside the quantification range.
Each plate included two kit controls, as well as three
internally identified quality control samples. From these, the
inter-assay CVs were monitored and controlled for being
510%. No measurements were removed by the lab.
Distribution of the values in the cohort without baseline
RKOA is presented in the Appendix.
Statistical analysis
Five hundred and ninety-three patients had no KOA (K/L
grade 0 in either knee at baseline) and available sCOMP data.
A repeated measures logistic regression model was used
where the outcomes were recorded at 5, 10, 15 and 20-years
follow-up. The primary exposure of interest in this model was
sCOMP levels (categorised into quartiles due to the non-
linear effect of sCOMP on outcomes). This model estimates
the impact of predictors on the average outcome over the 4
follow-up time points. An interaction of terms was fitted
between sCOMP and follow-up time to assess whether the
association of sCOMP on outcome changed between 5 and
20-years follow-up. This technique allowed us to include
participants meeting baseline inclusion criteria with complete
radiographic and pain follow-up data set available (n¼ 328),
along with those who had data available during any 5-year
interval follow-up over 20 years. This method allowed us to
utilise the longitudinal data with interval-censored data when
precise time to RKOA was not available. The models were
adjusted for age and BMI. We reported risks using odds ratios
(OR) and adjusted predictions for each sCOMP quartile
during 5-year intervals. This was performed using STATA/IC
package version 12.1 (StataCorp., College Station, TX).
Potential confounders
We assessed information on potential confounders at Y1.
Covariates, including age and BMI, were incorporated into
the analysis. Health-related behaviours that have been shown
to modify incidence of RKOA or levels of sCOMP were
assessed: physical activity at baseline and smoking status.
Physical activity was assessed via the following question:
‘‘How many times per week are you engaged in activity that
makes you sweat?’’ The participant was classified as active if
she reported more than an hour of strenuous activity each
week. Smoking habits were divided into the categories of
non-smoker or currently smoking. Non-steroidal anti-inflam-
matory drug (NSAIDs) use was coded as a dichotomous
variable.
Results
Of the original 1003 women who were seen at baseline, 970
underwent radiography at baseline and 750 had a baseline K/
L score of 0 (Figure 1). Of these, 646 had at least 1 follow-up
X-ray and 377 had X-rays at 20 years. Five hundred and
ninety-three women had a baseline and follow-up radiographs
and serum COMP measured at years 2 or 3. Comparison of
women’s characteristics who have not been included into
analyses (due to lack of biomarker data or loss to follow-up)
with those who have had been is summarised in Table 1
(Appendix).
Distribution of potential confounders of the study sample
(n¼ 593) according to quartiles of the sCOMP levels is
summarised in Table 2. Subjects with the 1st quartile of
COMP were younger (mean age 52 versus 55) and slimmer
(mean BMI 23 versus 26) when compared to the fourth. There
were no significant differences in terms of physical activity
levels, NSAID use, smoking, previous knee injury history or
type of work undertaken.
Radiographic OA
The cumulative incidence of RKOA was 8% by year 5, 24%
by year 10, 36% by year 15 and 81% by year 20. A significant
independent association was found between higher sCOMP
quartile incidence of RKOA (OR¼ 1.97, 95% confidence
interval (CI)¼ 1.33–2.91) when compared with the lowest
sCOMP quartile (Figure 2).
Painful radiographic OA
A significant independent association was found between the
highest quartile compared to the lowest quartile of sCOMP
quartile (OR 1.8 with 95% CI: 1.18–2.75) (Figure 3). After
adjusting for age and BMI, women with the highest baseline
quartile of sCOMP levels had a 48% increase in the risk of
developing painful RKOA, compared to women with the
lowest sCOMP level, which has become borderline significant
(OR¼ 1.48 with 95% CI 0.95–2.3).
Interestingly, a significant independent association was
found between the higher sCOMP quartile and risk of
developing painful RKOA (OR¼ 1.95, 95% CI¼ 1.25–3.05)
when compared with the third sCOMP quartile.
We found a similar association when we used 15 or more
days of pain to classify symptomatic RKOA. The association
between the baseline fourth quartile and risk of developing
symptomatic RKOA was non-significant (OR¼ 1.27 with
95% CI¼ 0.74–2.2) when compared with the first quartile of
sCOMP. However, the association between the highest
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Figure 1. The Venn diagrams illustrate the
relationship between the radiographic, pain-
ful and symptomatic KOA, during each
follow-up visit of the cohort with no RKOA
at baseline (n¼ 593). RKOA, radiographic
knee osteoarthritis; painful RKOA, any knee
pain reported in the last month and K/L score
2 on the same site; symptomatic RKOA,
knee pain for 15 d or more in the last month
and the K/L score 2.
Table 1. Comparison of women’s characteristics who have not been included into analyses (due to lack of biomarker data
or loss to follow-up) with those who have had been.
Characteristic
Included into analysis
(n¼ 593)
Not included into
analysis (n¼ 157) p value
sCOMP levels (U/L) 2.7–43.3 13.9 N/A
Age, years, mean (SD) 53.2 (5.7) 54.7 (6.5) 0.005
Body mass index, mean (SD) 24.9 (3.7) 25.9 (4.42) 0.146
Smoking (%) 0.300
Non-smoker 55% 53%
Ex-smoker 23.9% 21%
Current smoker 21% 26%
Alcohol units per week (%) 0.945
0 29% 35%
1–14 68% 58%
414 2.8% 7%
Manual/non-manual work (%) 0.668
Manual 17.3% 16%
Non-manual 82.6% 84%
Previous knee injury n (%) 57 (10.7) 19 (14) 0.3468
Physical activity, (41 h of strenuous
physical activity a week) n (%)
105 (18) 29 (19) 0.846
Non-ASA NSAIDs medication n (%) 0.571
No 563 (96) 108 (95)
Yes 24 (4) 6 (5)
Creatinine mg/L, mean(SD) 830 (433) 659 (116)
SD, standard deviation; NSAIDs, non-steroidal anti-inflammatory drugs.
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quartile and the risk remained statistically significant in
multivariate analysis when compared with the third quartile
(OR¼ 2.05 with 95% CI¼ 1.15–3.67) (Figure 4).
Discussion
This study demonstrated that the highest sCOMP quartile
predicts the incidence of RKOA over 20 years in the cohort of
middle-aged women with no baseline KOA. The associ-
ation between the highest quartile of sCOMP with the
incidence of painful and symptomatic KOA was significant
in multivariate analyses only when it was compared to the
third quartile.
Our study supports the previously reported significant
association between baseline high sCOMP levels and the risk
of developing RKOA in the cohorts with K/L52 at baseline
and follow-up to 10 years (Blumenfeld et al., 2013; Valdes
et al., 2014) and additionally shows that this relationship is
significant over a period of 20 years of follow-up, independ-
ent of baseline age and BMI in a cohort with no baseline knee
OA (K/L 0). This is an important difference from previous
studies, as K/L 1 has been shown to be one of the strongest
predictors of future RKOA as defined by K/L42 (Kerkhof
et al., 2014).
Despite the significant variability, self-reported knee pain
in KOA has been associated with structural radiographic
changes (Soni et al., 2012). Interestingly, despite significantly
increased the incidence of RKOA over time in our cohort, we
found that the majority of the patients with RKOA reported
Table 2. Women’s characteristics across sCOMP quartiles.
Characteristics
First COMP quartile
(n¼ 149)
Second COMP quartile
(n¼ 148)
Third COMP quartile
(n¼ 149)
Fourth COMP
quartile (n¼ 147) p value
sCOMP levels (U/L) 2.7–7.6 7.7–9.4 9.5–11.8 11.9–42
Age, years, mean (SD) 51.9 (5.6) 52.9 (6.0) 53.0 (5.5) 55.2 (5.3) 0.000
Body mass index, mean (SD) 23.9 (3.1) 25.2 (3.6) 24.7 (3.7) 25.9 (4.2) 0.004
Smoking (%) 0.743
Non-smoker 60% 54% 52% 55%
Ex-smoker 21% 24% 26% 25%
Current smoker 19% 22% 22% 20%
Alcohol units per week, (%) 0.259
0 24% 23% 34% 36%
1–14 73% 75% 62.5% 61%
414 2% 2% 3.5% 3%
Manual/non-manual work (%) 0.679
Manual 15% 15% 25.5% 17.5%
Non-manual 85% 85% 74.5% 82.5%
Previous knee injury (n) 14 11 14 18 0.490
Physical activity, (41 h of strenuous
physical activity a week) n (%)
28 (19) 17 (12) 32 (21.4) 28 (19) 0.125
Non-ASA NSAIDs medication n (%) 0.792
No 143 (96) 140 (95) 140 (94) 140 (95)
Yes 4 (3) 6 (4) 7 (5) 7 (5)
Creatinine mg/L, mean(SD) 844 (468) 867 (442) 824 (391) 786 (429) 0.467
SD, standard deviation; NSAIDs, non-steroidal anti-inflammatory drugs.
Figure 2. Serum COMP quartile sand the risk
of developing RKOA. The results are
adjusted for baseline age and BMI. The
bottom line consists of the overlapping lines
for the first and second sCOMP quartiles.
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no pain in the affected knee and only a small minority report a
significant knee pain (15 d or more), during each 5-year
follow-ups over 20-years.
We also demonstrated that high sCOMP levels are a
predictor of subsequent structural knee changes, but that
individuals with middle range levels of sCOMP (third
quartile) are less likely to develop painful KOA.
Unlike other forms of arthritis linked with inflammation,
knee OA is characterised by new bone formation (Suri &
Walsh, 2012). Knee pain linked with osteophytes is likely
representing unsuccessful remodelling process probably
mediated by inflammatory responses (Daghestani et al.,
2015; Ene et al., 2015; Stoppiello et al., 2014).
Radiographic changes without any significant symptoms
might be also associated with high makers of tissue turnover
(Karsdal et al., 2014). Differences between the probability of
developing painful or symptomatic RKOA in fourth and third
quartile of sCOMP might reflect those differences between a
successful and failed remodelling/repair process in KOA.
Strengths and potential limitations
This cohort study is representative for the UK population
of middle-aged women. With 5-year interval follow-up
knee radiographs obtained over 20 years, and self-reported
knee pain data collected contemporaneously, this is by far
the longest observational study data looking at the
predictive value of sCOMP for the development of
KOA. A discrete-time survival analysis model used in
this study allowed us to maximise the utility of follow-up
data available.
The research has some limitations, including losses to
follow-up and results being limited to women only. The serial
Figure 3. Serum COMP quartiles and the risk
of developing painful RKOA. The results are
adjusted for baseline age and BMI.
Figure 4. Serum COMP quartiles and the risk
of developing symptomatic RKOA. The
results are adjusted for baseline age and BMI.
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knee radiographs were not obtained in the semiflexed AP
view, as they were not available 25 years ago when the study
started and for consistency the same technique was used
during follow-up. The levels of sCOMP can reflect morpho-
logical and pathological changes in any cartilaginous joint.
In this study, we did not assess osteoarthritis affecting other
joints.
Loss of follow-up represents a major limitation in all long-
term cohort studies. There is potential for bias due to subjects’
mortality, or withdrawal, and the general selection of a
healthier cohort to attend the follow-up visits. We minimised
this healthier selection bias by using an analysis model that
allowed us to include results from all individuals who met
baseline inclusion criteria and attended any 5-year interval
follow-up over 20 years.
Conclusion
In a population of middle-aged women without baseline
RKOA, the highest sCOMP levels were linked with an
increased risk of developing structural changes consistent
with RKOA and painful KOA over 20 years. This study
highlights the fact that further research is needed to under-
stand differences in markers of tissue turnover to differentiate
populations at risk of developing radiographic and painful
RKOA.
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Appendix
Serum Cartilage Oligomeric Matrix Protein
Distribution
Serum cartilage oligomeric matrix protein quartile values in a population
of middle-aged women without KOA.
Quartile Minimum Maximum
1 2.7 7.6
2 7.7 9.4
3 9.5 11.8
4 11.9 43
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